<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Techniques and interpretation of measurement of the CD4 cell count in people with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Techniques and interpretation of measurement of the CD4 cell count in people with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Techniques and interpretation of measurement of the CD4 cell count in people with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>CD4 T cell laboratory testing through flow cytometry is considered an important part of HIV care since this parameter is used to stage disease and inform clinical management. With few exceptions, infectious and neoplastic complications of HIV disease are more common in patients with lower CD4 cell counts, so the results can guide clinicians as to how concerned they should be about a certain diagnosis. In addition, certain CD4 cell thresholds are used as benchmarks to either initiate or discontinue prophylaxis against opportunistic infections (OIs). These thresholds were previously used as an indication to begin antiretroviral therapy (ART); however, they now provide a sense of the urgency to start ART. </p><p>This topic will address flow cytometry and other techniques for measuring CD4 cells and the various factors that can lead to variations in CD4 cell counts, such as medications, infections, and other conditions. Issues related to the immunology and pathogenesis of HIV infection and the use of HIV RNA testing are discussed elsewhere. Guidance on when to start ART or OI prophylaxis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3743.html" rel="external">"Techniques and interpretation of HIV-1 RNA quantitation"</a> and  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p class="headingAnchor" id="H800928"><span class="h1">BACKGROUND</span></p><p class="headingAnchor" id="H15695274"><span class="h2">CD4 and CD8 T cells</span><span class="headingEndMark"> — </span>Human T lymphocytes can be functionally divided into cells that provide help for other immune cells and those that mediate cellular cytotoxicity. Helper T lymphocytes express cluster determinant 4 (abbreviated as "CD4") whereas cytotoxic T cells express cluster determinant 8 (abbreviated as "CD8"). The CD4 and CD8 molecules are members of the immunoglobulin superfamily and mediate adhesion to major histocompatibility complex class II and class I molecules, respectively. In addition, CD4 and CD8 amplify stimulatory signals through the T cell receptor [<a href="#rid1">1-3</a>]. </p><p>A CD4:CD8 ratio is calculated by dividing the number of CD4+ T cells by the number of CD8+ T cells; this ratio is usually greater than 1 in immunocompetent individuals [<a href="#rid4">4</a>]. However, in HIV infection, the CD4:CD8 ratio is usually less than 1. This reflects increasing numbers of CD8+ T cells and depletion of CD4+ T cells in chronic infection. This ratio usually increases with the initiation of antiretroviral therapy (ART) although the CD4:CD8 ratio normalizes in only a minority of patients [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H801004"><span class="h2">How does HIV affect CD4 T cells?</span><span class="headingEndMark"> — </span>HIV infection leads to severe depletion of CD4 T cells in the gut-associated lymphoid tissue with subsequent reduced levels of circulating CD4 lymphocytes in the peripheral blood [<a href="#rid6">6</a>]. CD4 cells are reduced precipitously in acute HIV infection, but usually rebound in the blood over several weeks as HIV-specific CD8 T cells help to lower plasma viremia [<a href="#rid7">7</a>]. In the untreated patient, CD4 T cells subsequently decline over several years. Population-based studies of the natural history of HIV infection among men who have sex with men (MSM) show that the mean CD4 count prior to seroconversion is about 1000 cells/microL; CD4 counts decline to a mean of 780 cells/microL at six months post-seroconversion and to 670 cells/microL at one year of follow-up [<a href="#rid8">8</a>]. Subsequently, the CD4 cell count declines at an average yearly rate of approximately 50 cells/microL, but there is substantial variation among patients [<a href="#rid8">8-10</a>]. Significant depletion of CD4 T cells can lead to opportunistic infections and mortality in the untreated patient. In addition, in one report, low baseline CD4 counts were associated with increased rates of virologic failure [<a href="#rid11">11</a>]. The stages and natural history of HIV infection are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF CD4 T CELL DEPLETION IN HIV INFECTION</span><span class="headingEndMark"> — </span>Although other viruses can infect CD4 T cells, HIV selectively targets and infects activated, expanding CD4 T cells [<a href="#rid12">12</a>].</p><p>During acute infection, viral replication occurs at an extremely rapid rate, often producing the highest level of circulating virus observed at any time during infection [<a href="#rid13">13</a>]. Rapidly proliferating virus-specific CD4 T cells become activated and expand in the presence of high viremia, resulting in subsequent infection, functional impairment, and death of these CD4 T cells. Viremia declines with the recruitment of HIV-specific CD8 T cells (host immune response) and depletion of the pool of susceptible CD4 cells.</p><p>Within the first weeks of infection there is a massive loss of T cells in the gut-associated mucosa associated with disruption of mucosal integrity [<a href="#rid14">14</a>]. This is followed by a progressive loss of CD4 cells in the peripheral blood, which is a hallmark of HIV infection. Disruption of the integrity of the gut mucosa is associated with translocation of microbial products from the gut, including lipopolysaccharide (LPS) [<a href="#rid14">14</a>]. This "leaky gut" is associated with chronic immune activation, as evidenced by markers of T cell activation (ie, CD38 and HLA-DR) [<a href="#rid15">15-17</a>]. </p><p>Treatment with antiretroviral therapy leads to viral suppression and immunologic improvement. The extent of the immune recovery is dependent in part on the degree of immune compromise prior to treatment. Incomplete immunologic recovery among patients with advanced disease may also be related to collagen formation in the gut and lymphoid tissues leading to disruption of normal architecture [<a href="#rid18">18,19</a>]. Other factors that influence immune recovery (eg, comorbid conditions, age) are reviewed below. (See <a class="local">'The CD4 T cell response to antiretroviral therapy'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">TECHNIQUES FOR MEASURING CD4 CELL COUNTS</span><span class="headingEndMark"> — </span>The CD4 cell count is usually determined by flow cytometry in which blood specimens must be processed within 18 hours of collection.</p><p>Alternative systems include: FACS Count System (Becton Dickinson); VCS Technology/Coulter Cyto-Spheres (Coulter Corp); Zymmune CD4/CD8 Cell Monitoring Kit (Zynaxis Inc); and TRAx CD4 Test Kit (T Cell Diagnostics). These systems perform well compared with standard flow cytometry and are cheaper and less technically demanding [<a href="#rid20">20</a>]. </p><p>Absolute counts may differ when different assays are used, or even when done by the same test in different laboratories [<a href="#rid21">21</a>]. As a result, sequential samples that are processed using different methods or by different laboratories should be interpreted with caution.</p><p class="headingAnchor" id="H801717"><span class="h2">What is a normal CD4 cell count?</span><span class="headingEndMark"> — </span>The normal adult CD4 count for most laboratories falls in a range of 800 to 1050 cells/microL; however, when considering laboratory variations of two standard deviations, the normal CD4 count range falls within 500 to 1400 cells/microL [<a href="#rid22">22</a>]. This broad range in normal values reflects the fact that the CD4 cell count is the product of three variables: the white blood cell count, the percentage of lymphocytes, and the percentage of lymphocytes that bears the CD4 receptor. (See <a class="local">'Variability of CD4 cell counts'</a> below.)</p><p>Laboratory testing also reports CD4:CD8 ratios, which are usually greater than 1 in a normal host. (See <a class="local">'CD4 and CD8 T cells'</a> above.)</p><p class="headingAnchor" id="H801811"><span class="h2">Absolute CD4 counts and percentages in HIV infection</span><span class="headingEndMark"> — </span>Flow cytometry reports CD4 percentages; the absolute CD4 cell count is calculated by multiplying the percentage and the total white cell count (WBC). In general, these two numbers are concordant; corresponding values are listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>An absolute CD4 count &gt;500 cells/microL corresponds to a CD4 percentage of &gt;29 percent</p><p class="bulletIndent1"><span class="glyph">●</span>An absolute CD4 count between 200 to 500 cells/microL corresponds to a CD4 percentage of 14 to 28 percent</p><p class="bulletIndent1"><span class="glyph">●</span>An absolute CD4 count &lt;200 cells/microL corresponds to a CD4 percentage of &lt;14 percent</p><p></p><p>Laboratory testing in people with HIV typically demonstrates an inversed CD4:CD8 ratio of &lt;1. It is important for clinicians to be aware that significant changes in the total WBC will have an effect on the absolute CD4 cell count, while the CD4 percentage will remain the same. (See <a class="local">'Variability of CD4 cell counts'</a> below.)</p><p>People with HIV and a CD4 count &lt;200 cells/microL are classified as having AIDS and are at risk for opportunistic infections. More detailed discussions on the clinical findings of patients with AIDS and the prevention of opportunistic infections are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'AIDS and advanced HIV infection'</a> and  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p class="headingAnchor" id="H22439973"><span class="h2">What is a significant change in CD4 cell counts?</span><span class="headingEndMark"> — </span>A significant change (eg, 2 standard deviations) between two tests is approximately a 30 percent change in the absolute count or an increase or decrease in CD4 percentage by 3 percentage points [<a href="#rid23">23</a>]. An adequate response on treatment is defined as an increase in CD4 count in the range of 50 to 150 cells/microL per year. (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p><p class="headingAnchor" id="H34797445"><span class="h2">Definition of AIDS</span><span class="headingEndMark"> — </span>A CD4 count of &lt;200 cells/microL indicates the clinical stage of AIDS, which implies a high susceptibility to opportunistic infections, such as Pneumocystis pneumonia. Information on prophylaxis against opportunistic infections is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">VARIABILITY OF CD4 CELL COUNTS</span></p><p class="headingAnchor" id="H15695529"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Although CD4 cell count monitoring can be a major parameter that influences clinical management, there is significant intraindividual variability; prior to the era of antiretroviral therapy (ART), a study of 1020 untreated patients found that the intraindividual coefficient of variation averaged by 25 percent [<a href="#rid10">10</a>]. </p><p>As noted above, a number of factors other than HIV infection influence CD4 cell counts. Significant changes in the total WBC can lead to marked changes in the absolute CD4 cell count. Certain medications or infections associated with leukopenia may result in depression of the absolute CD4 cell count. In contrast, specific medications or infections which lead to leukocytosis can result in elevated CD4 cell counts. In such cases, the absolute CD4 cell count and percentage may be discordant. These types of changes do not indicate a true change in the patient’s immunologic status per se and should be interpreted with caution. If the CD4 cell count changes dramatically without significant changes in the CD4 percentage, the clinician needs to assess other factors that may be leading to artifactual changes in the absolute count. Flow cytometry results that would lead to a therapeutic intervention may need confirmation if the result is dramatically different from a prior result performed within three to six months. </p><p>The CD4 cell percentage is sometimes used to assess immune function instead of the absolute number since there is less variation with this parameter [<a href="#rid23">23,24</a>]. In the AIDS Clinical Trial Group laboratories, the within-subject coefficient of variation for the CD4 percentage was 18 percent compared with 25 percent for the CD4 cell count [<a href="#rid10">10</a>].</p><p>Even among healthy adults, there are seasonal or month-to-month changes in the CD4 cell count [<a href="#rid25">25</a>]. There are also diurnal changes with the lowest levels of CD4 cell counts in the evening and peak values in the morning [<a href="#rid26">26</a>]. These variations have only a minor impact on results of flow cytometry.</p><p class="headingAnchor" id="H5"><span class="h2">Factors that affect laboratory testing</span><span class="headingEndMark"> — </span>The CD4 count can be influenced by factors other than HIV infection. The following factors do not appear to have an appreciable effect on the CD4 cell count: gender, HIV risk category, or psychologic or physical stress [<a href="#rid22">22</a>]. However, several infectious and noninfectious causes can reduce or increase the CD4 cell count.</p><p class="headingAnchor" id="H22439763"><span class="h3">Infection</span><span class="headingEndMark"> — </span>Modest decreases in the CD4 cell count have been noted in various acute infections (eg, cytomegalovirus, EB virus, hepatitis B, tuberculosis, some bacterial infections, and histoplasmosis). A study of patients coinfected with HIV and HTLV-I found that CD4 cell counts were 80 to 180 percent higher than in controls with HIV at comparable levels of immunosuppression [<a href="#rid27">27</a>]. Some data suggest that hepatitis C virus (HCV) coinfection is associated with a less robust immune recovery after initiation of ART compared with patients who are HCV-seronegative [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection", section on 'Natural history'</a>.)</p><p class="headingAnchor" id="H22439770"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Depending on the effect of the medication on the total WBC count, absolute CD4 cell counts may rise or decline. These changes do not reflect true changes in the patient’s immunologic status.</p><p class="bulletIndent1"><span class="glyph">●</span>For example, declines in absolute CD4 cell counts have been observed in HIV/HCV coinfected patients who are undergoing interferon therapy; however, CD4 T cell percentages usually remain the same or increase throughout HCV therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In humans and laboratory animals, one dose of corticosteroids leads to a rapid and transient decline in the numbers of peripheral blood lymphocytes through a redistribution of circulating lymphocytes. This may lead to a profound drop in the absolute CD4 cell count [<a href="#rid29">29</a>]. With chronic administration however, corticosteroids may lead to a leukocytosis; this may in turn lead to an elevated absolute CD4 cell count. </p><p></p><p class="headingAnchor" id="H15694737"><span class="h3">Alcohol use</span><span class="headingEndMark"> — </span>Persons with alcohol use disorders may experience depression of CD4 cell counts, which improve after alcohol abstinence [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H22439816"><span class="h3">Chronic conditions</span><span class="headingEndMark"> — </span>In people with HIV, having a splenectomy, advanced liver disease, and/or splenomegaly can affect the CD4 count. In such patients, the CD4 percentage may be a more reliable indicator of immunologic status than the absolute CD4 count. Splenectomy may lead to a deceptively high CD4 count. In contrast, advanced liver disease can be associated with a decrease in the CD4 count, with a lower absolute CD4 cell count relative to the CD4 percentage [<a href="#rid31">31-33</a>]; this discordance may be related to splenic sequestration and lymphopenia. A more detailed discussion of other chronic conditions that cause CD4 lymphopenia is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3917.html" rel="external">"Idiopathic CD4+ lymphocytopenia", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H114430117"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Pregnancy can also affect CD4 testing. A longitudinal analysis was performed of 51 HIV seronegative patients who had CD4 cell count testing during pregnancy and the postpartum period; 25 HIV-negative nonpregnant controls were also selected [<a href="#rid34">34</a>]. The following results were found:</p><p class="bulletIndent1"><span class="glyph">●</span>The mean white blood cell count was elevated in pregnant subjects above that in the non-pregnant controls and this difference increased throughout the pregnancy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mean absolute lymphocyte cell count, lymphocyte percentage, and absolute CD4+ cell count were significantly lower during pregnancy than during the 12-week post-delivery period. In contrast, the mean absolute CD8 count was not significantly different. </p><p></p><p>These data are important to bear in mind when evaluating the person with HIV who is pregnant. In this situation, the absolute CD4 count should be interpreted in the context of the CD4 percentage. </p><p class="headingAnchor" id="H13746655"><span class="h1">THE CD4 T CELL RESPONSE TO ANTIRETROVIRAL THERAPY</span><span class="headingEndMark"> — </span>With antiretroviral therapy (ART) and effective viral suppression, the expected CD4 cell response is an increase of approximately 50 to 150 cells/microL at one year, followed by slower incremental increases of 50 to 100 cells/microL per year until a steady state level is reached [<a href="#rid23">23,35,36</a>]. The frequency of monitoring depends upon the patient's CD4 count and viral load, as well as the duration of ART. In some patients, monitoring CD4 cells while on therapy can be considered optional, provided there is viral suppression. A discussion of CD4 count monitoring in patients receiving ART is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'CD4 count'</a>.)</p><p>Factors that correlate with reduced CD4 recovery include older age, male sex, the type of ART used, and the presence of certain coinfections (eg, hepatitis C virus) [<a href="#rid28">28,37</a>]. In addition, some studies have demonstrated that the baseline CD4 cell count affects the extent of immune recovery, suggesting that patients with advanced immune compromise may have limited immunologic reserve [<a href="#rid38">38</a>]. When interleukin-2 was administered to people with HIV in conjunction with ART, there was an absolute increase in CD4 cell counts compared with ART alone, but no discernible clinical benefit [<a href="#rid39">39</a>]. </p><p>If ART is discontinued, there is generally a rapid viral load rebound and sharp decline in CD4 count with a decrease of up to 100 to 150 cells/microL in three to four months [<a href="#rid40">40-42</a>]. However, if a patient develops virologic rebound due to resistance while taking ART, the CD4 may not decline for months [<a href="#rid43">43</a>]. As a result, CD4 cell counts are not a reliable marker of virologic suppression or medication adherence, and in general, we do not make changes in ART based on CD4 changes. (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'Virologic response'</a> and  <a class="medical medical_review" href="/z/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">CD4 T CELL TESTING IN RESOURCE-LIMITED SETTINGS</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) recommends CD4 cell count monitoring to assess when to start prophylaxis against opportunistic infections and when to initiate antiretroviral therapy (ART) [<a href="#rid44">44</a>]. CD4 counts were previously advocated as a surrogate to monitor the response to ART; however, subsequent studies have shown that this, by itself, is an inadequate way to evaluate treatment response and that the viral load is also an invaluable parameter, when available [<a href="#rid41">41,42,45,46</a>].</p><p>The total lymphocyte count (TLC) is a crude surrogate for the CD4 cell count, but is advocated by the WHO in areas where flow cytometry may not be available. </p><p>Other alternatives to flow cytometry have been investigated in resource-poor areas: </p><p class="bulletIndent1"><span class="glyph">●</span>One study demonstrated that microcapillary flow cytometry correctly identified those individuals with a CD4 count &lt;200 cells/microL (95 percent sensitivity and 100 percent specificity) [<a href="#rid47">47</a>]. Although this technology is easier to use, requires little training of personnel, and is less expensive than flow cytometry, it still requires significant initial capital investment for the instrument. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manual immunobead-based methods have the advantage of only requiring routine light microscopy [<a href="#rid48">48</a>]. However, the results with this technique may be less reproducible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The "CD4 Select" method, which utilizes only an automatic hematoanalyzer to assess both CD4 absolute counts and percentages, was found to have greater than 90 percent correlation with standard flow cytometry [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">IDIOPATHIC CD4 LYMPHOCYTOPENIA</span><span class="headingEndMark"> — </span>Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome characterized by low CD4 cell counts that are unexplained by HIV infection or other known medical conditions. Criteria for the definition of this disorder are [<a href="#rid50">50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A CD4 count less than 300 cells/microL or a CD4 percentage less than 20 on two or more measurements</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of laboratory evidence of HIV infection</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of an alternative explanation for the CD4 lymphocytopenia</p><p></p><p>The characteristics of this syndrome are similar to HIV infection and include susceptibility to opportunistic infections and abnormalities of T cell homeostasis and chronic immune activation [<a href="#rid30">30,51,52</a>]. No etiologic infectious agent has been identified to date. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3917.html" rel="external">"Idiopathic CD4+ lymphocytopenia"</a>.) </p><p class="headingAnchor" id="H3598645715"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111622.html" rel="external">"Society guideline links: HIV screening and diagnostic testing"</a>.)</p><p class="headingAnchor" id="H105341770"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15448.html" rel="external">"Patient education: HIV/AIDS (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16937.html" rel="external">"Patient education: Tests to monitor HIV (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15695829"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – CD4 T cell laboratory testing through flow cytometry is considered an important part of HIV care since this parameter is used to stage disease and guide clinical management. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">The normal CD4 count for most laboratories falls in a range of 800 to 1050 cells/microL. Flow cytometry reports CD4 percentages; the absolute CD4 cell count is calculated by multiplying the percentage and the total white blood cell count (WBC). In general, these two numbers are concordant. (See <a class="local">'Absolute CD4 counts and percentages in HIV infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD4 depletion in setting of HIV infection</strong> – During acute HIV infection, virus titers are extremely high. Rapidly proliferating virus-specific CD4 T cells become activated and expand in the presence of high viremia, resulting in subsequent infection, functional impairment, and death of CD4 T cells. In the untreated person with HIV, CD4 T cells subsequently decline over several years. (See <a class="local">'Mechanisms of CD4 T cell depletion in HIV infection'</a> above.)</p><p></p><p class="bulletIndent1">A significant change (eg, two standard deviations) between two tests is approximately a 30 percent change in the absolute count or an increase or decrease in CD4 percentage by 3 percentage points. (See <a class="local">'What is a significant change in CD4 cell counts?'</a> above.)</p><p></p><p class="bulletIndent1">Significant depletion of CD4 T-cells can lead to opportunistic infections and mortality in the untreated patient. A CD4 count of &lt;200 cells/microL indicates the clinical stage of AIDS, which implies a high susceptibility to opportunistic infections, such as Pneumocystis pneumonia. (See <a class="local">'Definition of AIDS'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that can affect the CD4 count</strong> – A number of factors other than HIV infection influence CD4 cell counts. Significant changes in the total WBC can lead to marked changes in the absolute CD4 cell count. Certain medications or infections, which are associated with leukopenia, may result in depression of the absolute CD4 cell count. In contrast, specific medications or infections, which lead to leukocytosis, can result in elevated CD4 cell counts. These types of changes do not indicate a true change in the patient’s immunologic status per se and should be interpreted with caution. (See <a class="local">'Variability of CD4 cell counts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to antiretroviral therapy</strong> – With antiretroviral therapy and effective viral suppression, the expected CD4 cell response is an increase of approximately 50 to 150 cells/microL at one year, followed by slower incremental increases of 50 to 100 cells/microL per year until a steady state level is reached. The rate of increase in CD4 cells may be slower in certain patients (eg, those with severe immunocompromise at baseline). (See <a class="local">'The CD4 T cell response to antiretroviral therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H3699332468"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John G Bartlett, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miceli MC, von Hoegen P, Parnes JR. Adhesion versus coreceptor function of CD4 and CD8: role of the cytoplasmic tail in coreceptor activity. Proc Natl Acad Sci U S A 1991; 88:2623.</a></li><li><a class="nounderline abstract_t">Norment AM, Salter RD, Parham P, et al. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature 1988; 336:79.</a></li><li><a class="nounderline abstract_t">O'Rourke AM, Rogers J, Mescher MF. Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling. Nature 1990; 346:187.</a></li><li><a class="nounderline abstract_t">Margolick JB, Gange SJ, Detels R, et al. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42:620.</a></li><li class="breakAll">Leung, V, Gillis J, Raboud J, Ndumbi P, Tsoukas C, Klein M. Predictors of CD4/CD8 ratio normalization and its affect on health outcomes in the era of combination antiretroviral therapy (cART). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. Chica (Accessed on October 11, 2011).</li><li><a class="nounderline abstract_t">Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749.</a></li><li><a class="nounderline abstract_t">Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.</a></li><li><a class="nounderline abstract_t">Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165:352.</a></li><li><a class="nounderline abstract_t">Margolick JB, Muñoz A, Vlahov D, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA 1992; 267:1631.</a></li><li><a class="nounderline abstract_t">Hughes MD, Stein DS, Gundacker HM, et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28.</a></li><li><a class="nounderline abstract_t">Álvarez H, Mocroft A, Ryom L, et al. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study. Clin Infect Dis 2023; 77:593.</a></li><li><a class="nounderline abstract_t">Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95.</a></li><li><a class="nounderline abstract_t">Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33.</a></li><li><a class="nounderline abstract_t">Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.</a></li><li><a class="nounderline abstract_t">Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005; 191:694.</a></li><li><a class="nounderline abstract_t">Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400.</a></li><li><a class="nounderline abstract_t">Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.</a></li><li><a class="nounderline abstract_t">Nies-Kraske E, Schacker TW, Condoluci D, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009; 199:1648.</a></li><li><a class="nounderline abstract_t">Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456.</a></li><li><a class="nounderline abstract_t">Johnson D, Hirschkorn D, Busch MP. Evaluation of four alternative methodologies for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:522.</a></li><li><a class="nounderline abstract_t">Sax PE, Boswell SL, White-Guthro M, Hirsch MS. Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1121.</a></li><li><a class="nounderline abstract_t">Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 1993; 119:55.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on April 26, 2023).</li><li><a class="nounderline abstract_t">Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2:114.</a></li><li><a class="nounderline abstract_t">van Rood Y, Goulmy E, Blokland E, et al. Month-related variability in immunological test results; implications for immunological follow-up studies. Clin Exp Immunol 1991; 86:349.</a></li><li><a class="nounderline abstract_t">Malone JL, Simms TE, Gray GC, et al. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3:144.</a></li><li><a class="nounderline abstract_t">Schechter M, Harrison LH, Halsey NA, et al. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. JAMA 1994; 271:353.</a></li><li><a class="nounderline abstract_t">Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800.</a></li><li><a class="nounderline abstract_t">Bloemena E, Weinreich S, Schellekens PT. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol 1990; 80:460.</a></li><li><a class="nounderline abstract_t">Pol S, Artru P, Thépot V, et al. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. AIDS 1996; 10:1293.</a></li><li><a class="nounderline abstract_t">McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431.</a></li><li><a class="nounderline abstract_t">Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54:1798.</a></li><li><a class="nounderline abstract_t">Claassen CW, Diener-West M, Mehta SH, et al. Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis 2012; 54:1806.</a></li><li><a class="nounderline abstract_t">Towers CV, Rumney PJ, Ghamsary MG. Longitudinal study of CD4+ cell counts in HIV-negative pregnant patients. J Matern Fetal Neonatal Med 2010; 23:1091.</a></li><li><a class="nounderline abstract_t">Maartens G, Boulle A. CD4 T-cell responses to combination antiretroviral therapy. Lancet 2007; 370:366.</a></li><li><a class="nounderline abstract_t">Le Moing V, Thiébaut R, Chêne G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471.</a></li><li><a class="nounderline abstract_t">Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count &lt;200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010; 55:451.</a></li><li><a class="nounderline abstract_t">Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441.</a></li><li><a class="nounderline abstract_t">INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548.</a></li><li><a class="nounderline abstract_t">Hawley-Foss N, Mbisa G, Lum JJ, et al. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis 2001; 33:344.</a></li><li><a class="nounderline abstract_t">Bahrani A, Ramaswamy R, Oldfield EC 3rd. Effects of virologic rebound on CD4 cell counts. Clin Infect Dis 2001; 32:1231.</a></li><li><a class="nounderline abstract_t">Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837.</a></li><li><a class="nounderline abstract_t">Deeks SG, Hoh R, Grant RM, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315.</a></li><li class="breakAll">http://www.who.int/hiv/pub/arv/adult2010/en/index.html (Accessed on October 15, 2010).</li><li><a class="nounderline abstract_t">Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971.</a></li><li><a class="nounderline abstract_t">Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010; 201 Suppl 1:S16.</a></li><li><a class="nounderline abstract_t">Balakrishnan P, Solomon S, Mohanakrishnan J, et al. A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:23.</a></li><li><a class="nounderline abstract_t">Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003; 37:S25.</a></li><li><a class="nounderline abstract_t">Srithanaviboonchai K, Rungruengthanakit K, Nouanthong P, et al. Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals. J Acquir Immune Defic Syndr 2008; 47:135.</a></li><li><a class="nounderline abstract_t">Unexplained CD4 + T-lymphocyte depletion in persons without evident HIV infection--United States. Infect Control Hosp Epidemiol 1992; 13:618.</a></li><li><a class="nounderline abstract_t">Zonios DI, Falloon J, Bennett JE, et al. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood 2008; 112:287.</a></li><li><a class="nounderline abstract_t">Goto R, Shiota S, Kaimori R, et al. Disseminated nontuberculous mycobacterial infection in a patient with idiopathic CD4 lymphocytopenia and IFN-γ neutralizing antibodies: a case report. BMC Infect Dis 2023; 23:58.</a></li></ol></div><div id="topicVersionRevision">Topic 3740 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901411" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adhesion versus coreceptor function of CD4 and CD8: role of the cytoplasmic tail in coreceptor activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263576" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cell-cell adhesion mediated by CD8 and MHC class I molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2114552" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868499" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868499" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365096" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678387" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical and epidemiologic features of primary HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346152" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347321" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903975" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37052343" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986671" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : HIV preferentially infects HIV-specific CD4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647878" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute human immunodeficiency virus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17115046" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Microbial translocation is a cause of systemic immune activation in chronic HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15688282" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218162" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068581" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19432547" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598193" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Collagen deposition limits immune reconstitution in the gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548331" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of four alternative methodologies for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589131" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098929" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098929" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2495346" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1834381" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Month-related variability in immunological test results; implications for immunological follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967309" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904317" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117912" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115420" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883595" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205454" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460964" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460963" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20121393" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Longitudinal study of CD4+ cell counts in HIV-negative pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659332" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CD4 T-cell responses to combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865399" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105259" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A CD4+ cell count&lt;200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205456" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828532" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interleukin-2 therapy in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438900" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283815" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of virologic rebound on CD4 cell counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944569" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807713" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807713" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784460" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20225942" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885780" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12822129" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Monitoring of human immunodeficiency virus infection in resource-constrained countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18091046" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361504" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Unexplained CD4 + T-lymphocyte depletion in persons without evident HIV infection--United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456875" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36717786" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Disseminated nontuberculous mycobacterial infection in a patient with idiopathic CD4 lymphocytopenia and IFN-γneutralizing antibodies: a case report.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
